Instrument Inactif

Communiqués POZEN Inc.

Actions

US73941U1025

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

01/12/14	Sanofi : Pozen met fin à son accord de commercialisation sur 2 médicaments en développement	DJ
05/09/13	SANOFI : obtient les droits de commercialisation de médicaments développés par Pozen	DJ

Communiqués

02/02/16	POZEN : Announces Stockholder Approval of its Transaction with Tribute Pharmaceuticals Canada Inc.	PR
07/12/15	POZEN : And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals	PR
07/12/15	POZEN : and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals	MW
09/11/15	POZEN : Reports Third Quarter 2015 Results	BU
06/11/15	POZEN : and Tribute Announce Effectiveness of Registration Statement on Form S-4	BU
26/10/15	POZEN : to Announce Third Quarter 2015 Results on November 9, 2015	BU
15/09/15	POZEN : to Present at the Ladenburg Thalmann Healthcare Conference	BU
14/09/15	POZEN : Appoints James P. Tursi, M.D. Chief Medical Officer	BU
10/08/15	POZEN : Reports Second Quarter 2015 Results	BU
30/07/15	POZEN : Market Updates on Drug Manufacturers - Other Equities -- Isis Pharma, Endo Intl., Amarin, United Therapeutics, and POZEN	PR
27/07/15	POZEN : Announces August 10th Webcast of Second Quarter 2015 Results	BU
27/07/15	POZEN : Appoints Scott Charles Senior Vice President of Finance	BU
22/06/15	POZEN : Announces Key Leadership Additions	BU
08/06/15	POZEN : Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors	MW
08/06/15	POZEN : Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors	BU
02/06/15	POZEN : Forms an Irish Subsidiary and Enters into an Intangible Property Transfer Arrangement	BU
01/06/15	POZEN : Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO	BU
08/05/15	POZEN : Reports First Quarter 2015 Results	PU
08/05/15	POZEN : Reports First Quarter 2015 Results	BU
04/05/15	POZEN : Announces May 8th Webcast of First Quarter 2015 Results	BU
09/03/15	POZEN : Reports Fourth Quarter and Year End 2014 Results	BU
04/03/15	POZEN : Announces March 9th Webcast of Fourth Quarter and Year End 2014 Results	BU
04/02/15	POZEN : Announces Issuance of VIMOVO® Related Patent by the United States Patent and Trademark Office	BU
17/12/14	POZEN : SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pozen, Inc. - POZN	PR
17/12/14	POZEN : YOSPRALA™ Receives Complete Response Letter from The FDA	BU